PAVO, NCT05169437: Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors |
|
|
| Active, not recruiting | 2 | 22 | US | Niraparib, Zejula | Tempus AI, GlaxoSmithKline | Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer | 06/24 | 01/25 | | |